0.03
+23.81%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immutep
Its shares trade on ASX under the ticker IMM.AX. It has been listed since 23 June 1988. In the fiscal year to 30 June 2026, it reported revenue of A$14.6m and a net loss of A$79.3m. At that date it held total assets of A$83.3m and shareholders' equity of A$61.5m.
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in research, development and commercialization of licensed medical biotechnology. The company is also focused on development of immunotherapeutic products. The firm operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The firm is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jun 1988
- Employees
- 19
- Website
- immutep.com ↗
Leadership
Pay as last reported
- Dr. Russell HowardIndependent Non-Executive Chairman of the BoardA$163,519
- Mr. Marc VoigtChief Executive Officer, Executive Director, since 2012A$1.1m
- Mr. Peter MeyersIndependent Non-Executive Deputy Chairman of the BoardA$138,712
- Ms. Deanne MillerChief Operating Officer, General Counsel, Joint Company SecretaryA$565,233
- Dr. Frederic TriebelChief Scientific Officer, Executive Director, since 2014A$864,436
- Mr. Florian VoglChief Medical OfficerA$955,823
- Ms. Indira NaiduJoint Company Secretary
- Ms. Lis BoyceNon-Executive DirectorA$144,764
- Ms. Catherine StrongInvestor Relations, since 2019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 53
- Social
- 99
- Governance
- 16
- Women in the workforce
- 68%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immutep Ltd has a strong portfolio of potential immunotherapy drugs, which have shown promising results in early stage trials. These drugs have the potential to revolutionize cancer treatment by enhancing the body's immune response to fight the disease.
- The company has a highly skilled and experienced research and development team, bolstered by collaborations with renowned research institutions and academic partners. This allows Immutep to stay at the forefront of immunotherapy research and develop innovative solutions.
- Immutep also possesses valuable intellectual property rights and patents, providing a competitive advantage in the rapidly growing immunotherapy market.
Weaknesses
- Immutep Ltd currently relies heavily on investment and partnership funding to support its research and development efforts. A lack of diversification in funding sources could pose a risk if there are any disruptions or limitations in securing such funds.
- Due to the highly specialized nature of immunotherapy, there is a risk of potential regulatory hurdles and lengthy approval processes before Immutep's drugs can be commercialized and generate revenue.
- As a relatively small and emerging biopharmaceutical company, Immutep may face challenges in scaling up manufacturing capabilities and establishing a global presence to effectively compete with larger industry players.
Opportunities
- The growing demand for effective cancer treatment options, especially those that harness the power of the immune system, presents a significant market opportunity for Immutep Ltd. The increasing prevalence of cancer worldwide further strengthens this potential market.
- Immutep's partnerships with established pharmaceutical companies can provide access to additional resources, expertise, and distribution capabilities, facilitating the development and commercialization of its immunotherapy drugs.
- Expansion into new geographic markets and diversifying the application of immunotherapy drugs beyond cancer, such as autoimmune diseases, could open up further revenue streams for the company.
Threats
- The competitive landscape in the immunotherapy market is intense, with numerous companies investing heavily in research and development. Immutep Ltd faces the risk of being outpaced by competitors with more advanced therapies or greater financial resources.
- Market volatility and regulatory changes can impact investment sentiment and funding availability, which may affect Immutep's ability to continue its research and development activities at the desired pace.
- There is also the potential risk of unforeseen side effects or limited efficacy in clinical trials, which could hinder the approval and commercial success of Immutep's immunotherapy drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.